Next Article in Journal
N,N′-1,2-Phenylene-bis(3-tert-butylsalicylideneiminato)nickel (II)
Previous Article in Journal
Synthesis, Spectroscopic, and Thermal Analyses of 2-Oxo-1,2-dihydroquinolin-8-yl 4-chlorobenzoate
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Short Note

5-[(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-[[6-(trifluoromethyl)pyridin-3-yl]methyl]pyridin-2-amine Dihydrochloride Dihydrate

1
Selvita Services Sp. z o.o., Selvita Group, Bobrzynskiego 14, 30-348 Krakow, Poland
2
Institute of General, Theoretical and Inorganic Chemistry, University of Innsbruck, Innrain 80-82, A-6020 Innsbruck, Austria
3
Sandoz GmbH, Biochemiestr. 10, A-6250 Kundl, Austria
4
Institute of Pharmacy, University of Innsbruck, Innrain 52c, A-6020 Innsbruck, Austria
*
Author to whom correspondence should be addressed.
Molbank 2023, 2023(2), M1673; https://doi.org/10.3390/M1673
Submission received: 30 May 2023 / Revised: 15 June 2023 / Accepted: 16 June 2023 / Published: 19 June 2023
(This article belongs to the Section Structure Determination)

Abstract

:
The dihydrochloride salt of pexidartinib was synthesized and the crystal structure of its dihydrate was determined from single crystal data. The asymmetric unit consists of one formula unit. In the pexidartinib molecule, the N atom of the central pyridine ring and the pyridine-N atom of the pyrrolopyridine group are both protonated. The pexidartinib molecule forms N–H···O and N–H···Cl interactions with neighboring water molecules and chloride ions, respectively. Water/chloride (O–H···Cl) and water/water (O–H···O) interactions are also observed. Collectively, these intermolecular interactions result in a complex H-bonded framework structure.

1. Introduction

Pexidartinib (I), Scheme 1, is a kinase inhibitor drug used for the treatment of symptomatic tenosynovial giant cell tumor (TGCT), a rare type of joint tumor. It acts by inhibiting multiple receptor tyrosine kinases including colony-stimulating factor-1 receptor (CSF-1R), c-Kit proto-oncogene proteins (c-Kit) and fms-like tyrosine kinase-3 (Flt-3) [1,2]. FDA approval of this drug was granted in 2019 [3,4] and its monohydrochloride is being sold under the brand name Turalio.
The existence of solid forms of pexidartinib and of its monohydrochloride and dihydrochloride salts has been disclosed in the patent literature [5,6]. Herein we report the crystal structure of a dihydrate of pexidartinib dihydrochloride, (II)·2H2O (Scheme 1), which was produced in the course of a study aimed at optimizing synthetic procedures. Given the great therapeutic importance of pexidartinib, knowledge of the structure of (II)·2H2O and the analysis of its intermolecular interactions provide valuable information for further studies, e.g., the investigation of biological and physicochemical properties.

2. Results

Crystal data and structure refinement parameters are collected Table 1. The asymmetric unit of (II)·2H2O contains one formula unit consisting of one pexidartinib molecule, two chloride ions and two water molecules (Figure 1). The N atom of the central pyridine ring and that of the pyridine ring of the pyrrolopyridine group are both protonated. The molecular conformation is defined by the relative orientation of three nearly planar fragments. The central N,5-methylpyridin-2-amine group (C8 > C14, N3, N4) forms nearly orthogonal arrangements with both the pyrrolopyridine (C1 > C8, N1, N2) plane and with the 3-methylpyridine (C14 > C19, N5) unit as evidenced by angles of 84.69(4)° and 82.75(2)° between the respective mean planes. In addition, the C13–N4–C14–C15 bridge between the pyridine rings (C9 > C13, N3) and (C15 > C19, N5) displays a torsion angle of 89.9(3)°.
Both pyridinium NH groups form hydrogen bonds to water molecules, N2—H2N···O1 and N3—H3N···O2(−x + 1, −y + 1, −z + 1), whilst the other two NH functions are connected to chloride ions, N1—H1N···Cl2 and N4—H4N···Cl3 (Table 2, Figure 2). The first water molecule (O1) serves as a bridge between two chloride units via Cl2···H1OA—O1—H1OB···Cl3(x, −y + 1/2, z − 1/2). It also accepts a hydrogen bond from the other water molecule, O2—H2OA···O1. The latter is additionally H-bonded to a chloride ion, O2—H2OB···Cl3(x + 1, −y + 1/2, z − 1/2). Collectively, these classical H-bond interactions define a 3-dimensional framework in which the pexidartinib (Pdt) molecule serves as a four-connected node (connections: 2 × Cl and 2 × H2O). The first water molecule (O1) is also four-connected (1 × Pdt, 2 × Cl, 1 × H2O). By contrast, the second water molecule (O2) is a three-connected node (1 × Pdt, 1 × Cl, 1 × H2O), and the chloride ions are two- and three-connected (1 × Pdt, 1 × H2O and 1 × Pdt, 2 × H2O). An essential fragment of the H-bonded framework structure is shown in Figure 2.

3. Materials and Methods

5-[(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-[[6-(trifluoromethyl)pyridin-3-yl]methyl]pyridin-2-amine dihydrochloride (II) was prepared by following a published procedure [6,7] and as illustrated in Scheme 1.
NMR spectra were recorded on a Bruker UltraShieldTM 300 MHz spectrometer. 1H NMR (300 MHz, DMSO-d6) δ = 11.77 (d, J = 2.5 Hz, 1H), 9.12 (s, 1H), 8.81 (d, J = 2.1 Hz, 1H), 8.18 (d, J = 2.4 Hz, 1H), 8.09 (dd, J = 12.3, 2.3 Hz, 2H), 7.97–7.81 (m, 3H), 7.48 (d, J = 2.4 Hz, 1H), 7.07 (d, J = 9.2 Hz, 1H), 4.78 (s, 2H), 3.96 (s, 2H). The obtained NMR data were found to be in agreement with previously published data for (II) [6,7] (see Supplementary Materials).
HPLC measurements were carried out with a Shimadzu Nexera-i LC-2040C 3D system with DAD detector; Gemini-NX 3 µ C18 (4.6 × 50 mm) column; mobile phase A: water with 0.1% formic acid, B: acetonitrile with 0.1% formic acid, using a gradient (80:20 to 5:95); flow 0.5 mL/min. LC/Mass spectra were recorded using a Shimadzu LSMS-2020 system with a Single Quadrupole MS detector.
Single crystals suitable for X-ray structure determination were grown from a saturated solution of (II) in dioxane. Intensity data for the single crystal structure determination were recorded with a Bruker D8 Quest Photon 100 diffractometer using MoKα radiation (λ = 0.71073 Å). The crystal structure was solved by Direct Methods with SHELXT [8] and refined with least-squares techniques using SHELXL [9]. H atoms were identified in difference-Fourier maps and those bonded to carbon atoms were refined using a riding model with Uiso parameters set to 1.2Ueq(C). The H atom positions at N and O atoms were refined with distance restraints, N–H = 0.89(2) Å and O–H = 0.83(2) Å, and their Uiso parameters were refined freely.

Supplementary Materials

The following supporting information can be downloaded online: 1H NMR spectrum, HPLC data, LC-MS data and crystallographic data in Crystallographic Information File (CIF) format.

Author Contributions

Conceptualization, S.N. (Sven Nerdinger); formal analysis, K.W. and T.G.; investigation, W.K.-O., S.N. (Sandro Neuner) and K.W.; writing—original draft preparation, T.G.; writing—review and editing, T.G. and S.N. (Sven Nerdinger) All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

CCDC 2265163 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/structures.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Mok, S.; Koya, R.C.; Tsui, C.; Xu, J.; Robert, L.; Wu, L.; Graeber, T.G.; West, B.L.; Bollag, G.; Ribas, A. Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy. Cancer Res. 2014, 74, 153–161. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Tap, W.D.; Wainberg, Z.A.; Anthony, S.P.; Ibrahim, P.N.; Zhang, C.; Healey, J.H.; Chmielowski, B.; Staddon, A.P.; Cohn, A.L.; Shapiro, G.I.; et al. Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N. Engl. J. Med. 2015, 373, 428–437. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Lamb, Y.N. Pexidartinib: First Approval. Drugs 2019, 79, 1805–1812. [Google Scholar] [CrossRef] [PubMed]
  4. Roskoski, R. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. Pharmacol. Res. 2020, 152, 104609. [Google Scholar] [CrossRef] [PubMed]
  5. Ibrahim, P.N.; Visor, G.C. Solid Forms of a Compound Modulating Kinases. International Patent WO2016179415, 10 November 2016. [Google Scholar]
  6. Chen, M.; Zhang, Y.; Zou, P.; Zhang, X. Preparation of PLX3397 Hydrochloride Crystal Forms. International Patent WO2017215521, 21 December 2017. [Google Scholar]
  7. Li, H.; Li, Y.; Huang, X. Green Preparation of Pexidartinib as Tyrosine Kinase Inhibitor. China Patent CN113444083, 28 September 2021. [Google Scholar]
  8. Sheldrick, G.M. SHELXT—Integrated space-group and crystal-structure determination. Acta Crystallogr. A 2015, 71, 3–8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  9. Sheldrick, G.M. Crystal structure refinement with SHELXL. Acta Crystallogr. C 2015, 71, 3–8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Scheme 1. Formation of pexidartinib dihydrochloride (II).
Scheme 1. Formation of pexidartinib dihydrochloride (II).
Molbank 2023 m1673 sch001
Figure 1. Asymmetric unit of (II)·2H2O with non-H atoms depicted as ellipsoids at the 50% probability level and H atoms drawn as spheres of random size.
Figure 1. Asymmetric unit of (II)·2H2O with non-H atoms depicted as ellipsoids at the 50% probability level and H atoms drawn as spheres of random size.
Molbank 2023 m1673 g001
Figure 2. H-bonded framework viewed parallel to the crystallographic a axis.
Figure 2. H-bonded framework viewed parallel to the crystallographic a axis.
Molbank 2023 m1673 g002
Table 1. Crystal data and structure refinement.
Table 1. Crystal data and structure refinement.
Compound(II)·2H2O
Moiety formula(C20H17ClF3N5)2+ · 2Cl · 2H2O
Empirical formulaC20H21Cl3F3N5O2
Formula weight526.77
Temperature (K)183(2)
Wavelength (Å)0.71073
Crystal systemMonoclinic
Space groupP21/c
a (Å)5.4641(3)
b (Å)16.2163(10)
c (Å)26.3877(17)
β (°)93.0718(18)
Unit cell volume (Å3)2334.8(2)
Z/Z’4/1
Reflections collected/Rint34,479/0.0479
Data/restraints/parameters4145/8/331
Goodness-of-fit on F21.044
R1 [I > 2 σ(I)]0.0365
wR2 (all data)0.0879
Largest diff. peak and hole (e · Å−3)0.444 and −0.368
CCDC no.2265163
Table 2. Hydrogen bonds (Å and °).
Table 2. Hydrogen bonds (Å and °).
D—H···AdD—HdH···AdD···A<(DHA)
N1—H1N···Cl20.878(16)2.242(17)3.1109(19)171(2)
N2—H2N···O10.869(16)1.895(17)2.762(2)175(2)
N3—H3N···O2 i0.891(16)1.895(17)2.774(3)168(2)
N4—H4N···Cl30.871(16)2.267(17)3.138(2)178(2)
O1—H1OA···Cl20.836(17)2.182(19)3.0014(18)167(3)
O1—H1OB···Cl3 ii0.828(18)2.304(19)3.1217(18)169(3)
O2—H2OA···O10.854(18)1.902(19)2.754(2)176(3)
O2—H2OB···Cl3 iii0.851(18)2.35(2)3.1561(19)158(3)
Symmetry codes: (i) −x + 1, −y + 1, −z + 1; (ii) x, −y + 1/2, z − 1/2; (iii) x + 1, −y + 1/2, z − 1/2.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kozanecka-Okupnik, W.; Wurst, K.; Neuner, S.; Nerdinger, S.; Gelbrich, T. 5-[(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-[[6-(trifluoromethyl)pyridin-3-yl]methyl]pyridin-2-amine Dihydrochloride Dihydrate. Molbank 2023, 2023, M1673. https://doi.org/10.3390/M1673

AMA Style

Kozanecka-Okupnik W, Wurst K, Neuner S, Nerdinger S, Gelbrich T. 5-[(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-[[6-(trifluoromethyl)pyridin-3-yl]methyl]pyridin-2-amine Dihydrochloride Dihydrate. Molbank. 2023; 2023(2):M1673. https://doi.org/10.3390/M1673

Chicago/Turabian Style

Kozanecka-Okupnik, Weronika, Klaus Wurst, Sandro Neuner, Sven Nerdinger, and Thomas Gelbrich. 2023. "5-[(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-[[6-(trifluoromethyl)pyridin-3-yl]methyl]pyridin-2-amine Dihydrochloride Dihydrate" Molbank 2023, no. 2: M1673. https://doi.org/10.3390/M1673

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop